Tanta University Faculty of Medicine <u>Clinical Oncology Department</u>

Time allowed: 2 hours

M.Sc. Exam 2nd Part Clinical Oncology & Nuclear Medicine <u>Chemotherapy</u>

All Questions should be answered:

| | | | | | | | | | | Γ | vlarks |
|----|---|---|--------|-------|--------------|---------|--------|-------------|--------------|---------|--------|
| 1- | Tu | mors | can | be | classified | into | two | categories | according | to | their |
| | immunologic activities, hot tumors and cold tumors: | | | | | | | | | | |
| | a- | a- What are the hot and cold tumors? 5 | | | | | | | | | 5 |
| | b- | b- What are the problems we faced in cold tumors with immune therapy? 10 | | | | | | | | | ? 10 |
| | c- What are the solutions? | | | | | | | | | | 15 |
| | | | | | | | | | | | |
| 2- | HER2 over-expression is associated with increased cell proliferation: | | | | | | | | | | |
| | a- What is the role HER2 in the progression of breast cancer? | | | | | | | | | 5 | |
| | b- | b- What are the tests used to determine HER2 expression and what are the | | | | | | | | ire the | |
| | | differ | ence t | betwe | een them? | | | | | | 10 |
| | C- | What | is the | relat | tion betwee | n HER | 2 & to | opoisomeras | e-II genes? | | 10 |
| | d- | What | is the | trun | cated HER | 2? | | | | | 5 |
| | | | | | | | | | | | |
| 3- | Male patient with hormone resistant prostate cancer recommended to | | | | | | | | led to | | |
| | ree | ceive A | birat | eron | e Acetate | (Zytiga | a). De | scribe, | | | |
| | а- | Mech | anism | of a | ction | | | | | | 10 |
| | b- | Mech | anism | of r | esistance | | | | | | 10 |
| | C- | Instru | ction | of ac | lministratio | n | | | 191 - A 1 | | 10 |
| | | | | | | | | | | | |
| 4- | Bevacizumab is administered with multiple regimens of chemotherapy a | | | | | | | | | apy as | |
| | a 2 | and line | treat | men | t. What ar | e its m | ain to | oxicities? | | | 20 |
| | | | | | | | | | | | |

5- What are the indications, contraindication, and complications of enteral nutrition in cancer patients?25

2/11/2021

Tanta University Faculty of Medicine <u>Clinical Oncology Department</u>

9/11/2021

Time allowed: 2 Hours

M.Sc. Exam 2nd Part Clinical Oncology & Nuclear Medicine <u>Radiation Technology& Isotopes</u>

All Questions should be answered:

Marks

- 1- Describe and compare in details between different planning techniques of radiotherapy for breast cancer patients after breast conservation?
 40
- 2- Thirty-one year's female patient with cervical carcinoma mass 1.5x1.8 cm:
 - a- Define the last FIGO classification. 10
 - b- Describe how to manage the lady and 20
 - c- If the initial, mass was 2 x2.5 cm describe your suggestion by using different tools for treatment to achieve conservative management of this lady aiming to retain fertility in both scenarios
 15
- 3- Adjoining fields: explain in detail the problem and solution?How to apply in craniospinal irradiation?25
- 4- Radiotherapy delineation in cancer bladder? 25

Faculty of Medicine

Clinical Oncology Department

17/10/2021

Time allowed: 3 Hours

M.Sc. Exam 2nd Part

Clinical Oncology & Nuclear Medicine

1st paper

All Questions should be answered:

Marks

- 1- A 62 yrs. old man diagnosed with advanced lung cancer is going to start first-line chemotherapy. He has read on a popular magazine that fasting before and during chemotherapy is associated with reduced toxicity and enhanced efficacy of anticancer therapies.
- a- Would you advise the patient to fast before and during chemotherapy? WHY?
- b- Is this recommendation based on established clinical trials? Mention these trials?
- c- Is there a supplementation of specific nutrients enhance the effectiveness of first-line chemotherapy in lung cancer? Mention it, its effectiveness and dose?
- 2- Different treatment modalities of brain metastases in favorable versus poor prognosis patients?25
- 3- Enumerate the main conditions to consider in the differential diagnosis of multiple myeloma, and explain 3 of them?30
- 4- What are the types and clinical pictures of mediastinal tumours, and explain treatment of one of them?30

GOODLUCK

Faculty of Medicine

Clinical Oncology Department

20/10/2021

Time allowed: 3 Hours

M.Sc. Exam 2nd Part

Clinical Oncology & Nuclear Medicine

2nd Paper

All Questions should be answered:

Marks

1- A 65- years old male was recently diagnosed with an esophageal neuroendocrine carcinoma with innumerable metastases to liver and lymph nodes. the tumor is poorly differentiated with a ki67 of 70% with mitotic rate of 20 mitoses / 10 HPF

| a- What is the grade of this tumor? | 4 | | | | | |
|---|----|--|--|--|--|--|
| b- Which imaging study should be considered? | 6 | | | | | |
| c- Which laboratory tests should be done? | | | | | | |
| d- What are the treatment options for this case? | | | | | | |
| 2- Enumerate the most common side effect of pelvic radiotherapy | | | | | | |
| and:- | 10 | | | | | |
| a- Discuss one of the most common hematological and one of | | | | | | |
| the non-hematological side effects and how to correct. 6 | | | | | | |
| b- Describe technical methods to reduce the occurrence of the | | | | | | |
| pelvic side effect of radiotherapy. | 9 | | | | | |
| 3- Flare phenomenon in hormone dependent cancer patient? | 25 | | | | | |
| 4- What are the prognostic and predictive biomarkers in a patient | | | | | | |
| diagnosed with lung adenocarcinoma? And what are the recent | | | | | | |

advances in management of stage III NSCLC?

25

Faculty of Medicine

Clinical Oncology Department

23/10/2021

Time allowed: 90 minutes

M.Sc. Exam 2nd Part

Clinical Oncology & Nuclear Medicine

Optional Determinant

All Questions should be answered:

Marks

| 1- The | rational | of | organ | preserva | tion | in | anal | canal |
|--------|----------|------|-------|----------------|------|----|------|-------|
| carc | cinoma? | | | | | | | 25 |
| 2- Cor | nbined | chem | in | nasopharyngeal | | | | |
| carc | cinoma? | | | | | | | 25 |

carcinoma?

GOOD LUCK

Faculty of Medicine

Clinical Oncology Department

27/10/2021

Time allowed: 3 Hours

M.Sc. Exam 2nd Part

Clinical Oncology & Nuclear Medicine

Radiation Technology& Isotopes

All Questions should be answered:

Marks

- 1- In cranial irradiation, define the tolerances of organ at risk?25
- 2- Explain the role of radiopharmaceuticals agents in management of bone metastases?25
- 3- Adjuvant radiotherapy delineation in locally advanced cancer vulva? 25
- 4- Indications and contraindications of radioactive I¹³¹ in treatment of thyroid carcinoma and how to use it if indicated?
 25

GOOD LUCK

Tanta University Faculty of Medicine <u>Clinical Oncology Department</u>

Time allowed : 2 Hours

M.Sc. Exam 2nd Part Clinical Oncology & Nuclear Medicine <u>Radiation therapy</u>

All Questions should be answered:

Marks

30/10/2021

- 1- Role of radionuclide in treatment of neuroendocrine tumors? 35
- 2- What are the factors affecting toxicity of CNS irradiation? 30
- 3- Discuss late complications of head and neck cancer and their Management?40
- 4- Discuss the role of poistron emission tomography in cancer diagnosis and treatment?30